



SolAeroMed Inc
Research Transition Facility
3535 Research Rd NW
Calgary T2L 2K8

email: info@solaeromed.com
www.solaeromed.com

Newsletter #6 April 9, 2013

Dear SolAeroMed shareholders,

I am excited to be sending out another newsletter so soon - we have information which we hope will excite all SolAeroMed shareholders too.

Following recent positive developments, and with considered advice and approval of the Board, SolAeroMed management is planning to initiate a private placement to raise **\$1.5 million** to progress human clinical trials for safety (Phase I) and efficacy (Phase IIa) over the next 1-2 years.

The positive developments realized at SolAeroMed since our last financing include:

- Establishment of an experienced external Board of Directors
- Progression of a successful S-1226 Clinical Trial Application resulting in regulatory approval from Health Canada to proceed to Phase I human clinical trials
- Assurance from the regulators that S-1226 will not require additional time-consuming and expensive pre-clinical toxicology or efficacy studies.
- Issuance of the North American S-1226 patent.
- Acquisition of a 2nd respiratory drug candidate, S-1229, which offers exciting therapeutic applications.
- Over \$1 million in new grant funding to promote underlying research and development of both S-1226 and S-1229
- Continued low operating costs.
- Clarification of costs and time-lines for Phase I and Phase IIa S-1226 clinical studies.
- Increased clarity in understanding of our target markets for S-1226 and S-1229 which helps define our development and ultimate exit strategies.

We have also developed business relationships that are expected to support much of our ongoing operating costs by providing useful revenue generation which mitigates business risks in our overall development plan. This allows the majority of the proceeds of the

current financing to directly support Phase I and IIa clinical trials over the coming 1-2 years.

The board of directors have proposed that the price of SolAeroMed shares for this finance be in the region of \$4.25. This price represents an increase since our Oct 2011 financing (\$2.50/share) which we believe is fully justified by the progress summarized above.

We are planning to engage our current shareholders to determine interest in such a proposed financing. To further explain this offering to **Calgary based investors** we are scheduling a SolAeroMed presentation of our science and business development paths and aim to summarize the opportunity as well as risk associated with investment in SolAeroMed on **Tuesday April 30, 4-530pm**.¹ We intend this to be a small meeting and should provide ample opportunity for discussion.

We would like to hear from you if you plan to attend our presentation and meeting April 30. Alternatively, you are welcome to contact Joe Tucker or myself directly to answer any questions you may have.

Sincerely

John Dennis, CEO

ph +1 403 689 5989
email jdennis@solaeromed.com

Joe Tucker, CFO

ph +1 403 969 7999
email: jeltucker@aol.com

PS We will inform SolAeroMed shareholders of further developments through www.solaeromed.com.

¹ Tuesday April 30, 4-530pm, SolAeroMed board room, 3535 Research Rd NW